China Pharma vs China SXT Pharmaceuticals
CPHI and SXTC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CPHI and SXTC compare
China Pharma grew revenue faster over the last twelve months (−11.0% versus −34.6% for China SXT Pharmaceuticals).
China Pharma keeps more of each dollar of sales as profit, with a net margin of −114% compared with −545% at China SXT Pharmaceuticals.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CPHI | SXTC |
|---|---|---|
| Size and price | ||
| Market cap | $23.4M | – |
| Share price | $0.543 | $2.83 |
| Change, 1 year | −64.5% | −100.0% |
| Change, 5 years | −99.8% | −100% |
| Beta (5Y) | 0.89 | – |
| Employees | 221 | 56 |
| StockData Score | ||
| Total score | 4 | 4 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 | 1 |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 6.0× | – |
| P/B | 0.6× | – |
| Growth | ||
| Revenue growth (TTM) | −11.0% (better) | −34.6% |
| Revenue growth, 5Y average | −17.5% (better) | −24.9% |
| Profitability | ||
| Gross margin | 11.8% | 21.9% (better) |
| Operating margin | −112% (better) | −626% |
| Net margin | −114% (better) | −545% |
| Return on equity | −21.0% (better) | −27.5% |
| Return on invested capital | −15.5% (better) | −1657% |
| Financial health | ||
| Debt / equity | 0.05 | 0.03 (better) |
| Interest coverage | −136.5× | −113.1× (better) |
| Current ratio | 0.26 | 7.93 (better) |
| Altman Z-score | −0.30 | – |
| Piotroski F-score | 6 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 0.47% | – |
| Held by insiders | 0.00% | 0.00% |
| Short interest, % of float | 0.21% | 2.9% |
Go deeper
- CPHI stock overview
- CPHI income statement
- CPHI valuation and score
- SXTC stock overview
- SXTC income statement
- SXTC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.